TCM
VKTX icon

Tradewinds Capital Management’s Viking Therapeutics VKTX Stock Holding History

Tradewinds Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$1.05K – 737
2025
Q3 		$1.05K Buy
40
+30
+300% +$895 ﹤0.01% 568
2025
Q2 		$265 Hold
10
– – ﹤0.01% 586
2025
Q1 		$242 Hold
10
– – ﹤0.01% 617
2024
Q4 		$403 Buy
+10
New +$570 ﹤0.01% 604

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tradewinds Capital Management's VKTX Position: Q4 2025 in Review

Tradewinds Capital Management sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 40 shares — an estimated $1.05K sold.

Tradewinds Capital Management first reported a position in VKTX in Q4 2024 and held it in 4 quarters. The position peaked at $1.05K in Q3 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Tradewinds Capital Management reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tradewinds Capital Management sold 40 Viking Therapeutics shares in Q4 2025, an estimated $1.05K.
  • Tradewinds Capital Management first reported a position in Viking Therapeutics in Q4 2024 and held it in 4 quarters.
  • Tradewinds Capital Management's Viking Therapeutics position peaked at $1.05K in Q3 2025.
  • 427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Tradewinds Capital Management's 13F filing for Q4 2025, filed 14 Jan 2026.